Previous Article | Next Article 
J Virol. 1991 January; 65(1): 292-298
In vitro biological activities of the E6 and E7 genes vary among human papillomaviruses of different oncogenic potential.
M S Barbosa,
W C Vass,
D R Lowy and
J T Schiller
Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, Maryland 20892.
ABSTRACT
Human papillomavirus type 16 (HPV-16) and HPV-18 are often detected in cervical carcinomas, while HPV-6, although frequently present in benign genital lesions, is only rarely present in cancers of the cervix. Therefore, infections with HPV-16 and HPV-18 are considered high risk and infection with HPV-6 is considered low risk. We found, by using a heterologous promoter system, that expression of the E7 transforming protein differs between high- and low-risk HPVs. In high-risk HPV-16, E7 is expressed from constructs containing the complete upstream E6 open reading frame. In contrast, HPV-6 E7 was efficiently translated only when E6 was deleted. By using clones in which the coding regions of HPV-6, HPV-16, and HPV-18 E7s were preceded by identical leader sequences, we found that the ability of the E7 gene products to induce anchorage-independent growth in rodent fibroblasts correlated directly with the oncogenic association of the HPV types. By using an immortalization assay of normal human keratinocytes that requires complementation of E6 and E7, we found that both E6 and E7 of HPV-18 could complement the corresponding gene from HPV-16. However, neither E6 nor E7 from HPV-6 was able to substitute for the corresponding gene of HPV-16 or HPV-18. Our results suggest that multiple factors, including lower intrinsic biological activity of E6 and E7 and differences in the regulation of their expression, account for the low activity of HPV-6, in comparison with HPV-16 and HPV-18, in in vitro assays. These same factors may, in part, account for the apparent difference in oncogenic potential between these viruses.
J Virol. 1991 January; 65(1): 292-298
This article has been cited by other articles:
-
Goon, P, Sonnex, C
(2008). Frequently asked questions about genital warts in the genitourinary medicine clinic: an update and review of recent literature. Sex. Transm. Infect.
84: 3-7
[Abstract]
[Full Text]
-
Hasan, U. A., Bates, E., Takeshita, F., Biliato, A., Accardi, R., Bouvard, V., Mansour, M., Vincent, I., Gissmann, L., Iftner, T., Sideri, M., Stubenrauch, F., Tommasino, M.
(2007). TLR9 Expression and Function Is Abolished by the Cervical Cancer-Associated Human Papillomavirus Type 16. J. Immunol.
178: 3186-3197
[Abstract]
[Full Text]
-
Zou, Y., Sfeir, A., Gryaznov, S. M., Shay, J. W., Wright, W. E.
(2004). Does a Sentinel or a Subset of Short Telomeres Determine Replicative Senescence?. Mol. Biol. Cell
15: 3709-3718
[Abstract]
[Full Text]
-
Steller, M. A.
(2002). Cervical Cancer Vaccines: Progress and Prospects. Reproductive Sciences
9: 254-264
[Abstract]
-
Degenhardt, Y. Y., Silverstein, S.
(2001). Interaction of Zyxin, a Focal Adhesion Protein, with the E6 Protein from Human Papillomavirus Type 6 Results in Its Nuclear Translocation. J. Virol.
75: 11791-11802
[Abstract]
[Full Text]
-
Menzo, S., Monachetti, A., Trozzi, C., Ciavattini, A., Carloni, G., Varaldo, P. E., Clementi, M.
(2001). Identification of Six Putative Novel Human Papillomaviruses (HPV) and Characterization of Candidate HPV Type 87. J. Virol.
75: 11913-11919
[Abstract]
[Full Text]
-
Degenhardt, Y. Y., Silverstein, S. J.
(2001). Gps2, a Protein Partner for Human Papillomavirus E6 Proteins. J. Virol.
75: 151-160
[Abstract]
[Full Text]
-
Tornesello, M. L., Buonaguro, F. M., Buonaguro, L., Salatiello, I., Beth-Giraldo, E., Giraldo, G.
(2000). Identification and functional analysis of sequence rearrangements in the long control region of human papillomavirus type 16 Af-1 variants isolated from Ugandan penile carcinomas. J. Gen. Virol.
81: 2969-2982
[Abstract]
[Full Text]
-
Zimmermann, H., Degenkolbe, R., Bernard, H.-U., O'Connor, M. J.
(1999). The Human Papillomavirus Type 16 E6 Oncoprotein Can Down-Regulate p53 Activity by Targeting the Transcriptional Coactivator CBP/p300. J. Virol.
73: 6209-6219
[Abstract]
[Full Text]
-
Greenstone, H. L., Nieland, J. D., de Visser, K. E., De Bruijn, M. L. H., Kirnbauer, R., Roden, R. B. S., Lowy, D. R., Kast, W. M., Schiller, J. T.
(1998). Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model. Proc. Natl. Acad. Sci. USA
95: 1800-1805
[Abstract]
[Full Text]
-
Meschede, W., Zumbach, K., Braspenning, J., Scheffner, M., Benitez-Bribiesca, L., Luande, J., Gissmann, L., Pawlita, M.
(1998). Antibodies against Early Proteins of Human Papillomaviruses as Diagnostic Markers for Invasive Cervical Cancer. J. Clin. Microbiol.
36: 475-480
[Abstract]
[Full Text]
Copyright © 1991 by the American Society for Microbiology. All rights reserved.